http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
PureTech Announces Annual Results for Year Ended December 31, 2025
-
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange
-
Seaport Therapeutics appoints Dr. Sharon Mates to board of directors
-
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
-
PureTech reports positive data from cancer drug trial
-
PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)
-
PureTech Health: Notice of Results
-
PureTech publishes phase 2b trial results for lung fibrosis drug
-
PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
-
Seaport Therapeutics reports positive phase 1 results for anxiety drug
-
PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers
-
Seaport Therapeutics publishes data on oral allopregnanolone prodrug
-
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutical
-
PureTech to Present at the Leerink Partners Global Healthcare Conference
-
PureTech receives orphan drug designations for IPF treatment
-
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
-
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference
-
PureTech Health names Robert Lyne as permanent CEO
-
PureTech Appoints Robert Lyne as Chief Executive Officer
-
PureTech gets FDA feedback supporting phase 3 trial for lung drug
-
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
-
Gallop Oncology reports positive Phase 1b trial results for LYT-200
-
PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
-
Gallop Oncology to present AML trial data at ASH meeting
-
PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) A
-
PureTech Health Plc (PRTC) Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone
-
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
-
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
-
Seaport Therapeutics begins Phase 1 trial of anxiety disorder drug
-
PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volun
-
PureTech Health plc – Half-Year Report
-
PureTech launches Celea to advance lung fibrosis drug
-
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
-
PureTech Health: Notice of Half-Yearly Results
-
Vedanta Biosciences' ulcerative colitis drug fails phase 2 trial
-
Vedanta's VE202 fails phase 2 ulcerative colitis trial primary endpoint
-
PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
-
PureTech launches Celea Therapeutics for respiratory disease treatments
-
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
-
Seaport Therapeutics begins Phase 2b study of depression drug GlyphAllo
-
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
-
PureTech Announces Leadership Transition
-
PureTech Health chairman Raju Kucherlapati steps down from board
-
PureTech Announces Board Change
-
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
-
PureTech Health: Results of Annual General Meeting
-
PureTech to Present at the Jefferies Global Healthcare Conference
-
PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
-
PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
-
PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
